• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to M.A.N. Şendur et al and J. Michels.

作者信息

Penson David F, Armstrong Andrew J, Concepcion Raoul, Agarwal Neeraj, Olsson Carl, Karsh Lawrence, Dunshee Curtis, Wang Fong, Wu Kenneth, Krivoshik Andrew, Phung De, Higano Celestia S

机构信息

David F. Penson, Vanderbilt University and the VA Tennessee Valley Geriatric Research, Education, and Clinical Center, Nashville, TN; Andrew J. Armstrong, Duke University, Durham, NC; Raoul Concepcion, Urology Associates PC, Nashville, TN; Neeraj Agarwal, University of Utah, Salt Lake City, UT; Carl Olsson, Icahn School of Medicine at Mount Sinai, New York, NY; Lawrence Karsh, The Urology Center of Colorado, Denver, CO; Curtis Dunshee, Urological Associates of Southern Arizona, Tucson, AZ; Fong Wang and Kenneth Wu, Medivation, San Francisco, CA; Andrew Krivoshik, Astellas Pharma Global Development, Northbrook, IL; De Phung, Astellas Pharma Global Development, Leiden, Netherlands; and Celestia S. Higano, University of Washington, Seattle, WA.

出版信息

J Clin Oncol. 2017 Jan;35(1):123. doi: 10.1200/JCO.2016.69.9371. Epub 2016 Oct 31.

DOI:10.1200/JCO.2016.69.9371
PMID:28034066
Abstract
摘要

相似文献

1
Reply to M.A.N. Şendur et al and J. Michels.对M.A.N. 森杜尔等人及J. 米歇尔的回复。
J Clin Oncol. 2017 Jan;35(1):123. doi: 10.1200/JCO.2016.69.9371. Epub 2016 Oct 31.
2
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.回复盐田正树和横沟晃的致编辑信：关于罗伯特·J·范·索斯特、埃伦·S·德·莫雷、夏洛特·F·克韦尔丹等人的研究“靶向雄激素受体在去势抵抗性前列腺癌中赋予恩杂鲁胺和多西他赛之间的体内交叉耐药性，但卡巴他赛不存在这种情况”。《欧洲泌尿外科杂志》2015年；67卷：981 - 985页
Eur Urol. 2016 Mar;69(3):e43-4. doi: 10.1016/j.eururo.2015.07.024. Epub 2015 Jul 30.
3
Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.回复：罗伯特·J·范·索斯特、埃伦·S·德·莫雷、夏洛特·F·克韦尔丹等。在去势抵抗性前列腺癌中，靶向雄激素受体可导致恩杂鲁胺和多西他赛之间产生体内交叉耐药，但卡巴他赛不会。《欧洲泌尿外科杂志》2015年；67卷：981 - 985页。
Eur Urol. 2016 Mar;69(3):e41-2. doi: 10.1016/j.eururo.2015.07.025. Epub 2015 Jul 26.
4
Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Eur Urol. 2015 Dec;68(6):e132-3. doi: 10.1016/j.eururo.2015.08.018. Epub 2015 Aug 28.
5
Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.回复：纳迪尔·纳库齐、西尔维斯特·勒穆莱克、劳伦斯·阿尔比热斯等。在多西他赛治疗后进展且随后接受新型雄激素受体途径靶向治疗的患者中，卡巴他赛仍具有活性。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2014.04.015 。
Eur Urol. 2014 Oct;66(4):e71-2. doi: 10.1016/j.eururo.2014.06.038. Epub 2014 Jul 8.
6
Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.回复：奥拉齐奥·卡福、乌戈·德·乔治、露西亚·弗拉蒂诺等。多西他赛及其他二线治疗失败后作为三线或四线治疗的去势抵抗性前列腺癌治疗的临床结果：一项意大利多中心研究的结果。《欧洲泌尿外科杂志》2015年；68卷：147 - 153页
Eur Urol. 2015 Dec;68(6):e129-31. doi: 10.1016/j.eururo.2015.08.017. Epub 2015 Aug 28.
7
Enzalutamide in castration-resistant prostate cancer.恩杂鲁胺治疗去势抵抗性前列腺癌
Lancet Oncol. 2014 Jul;15(8):e312. doi: 10.1016/s1470-2045(14)70251-7.
8
Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer.恩杂鲁胺：一种用于非转移性去势抵抗性前列腺癌的新适应证。
Asian J Androl. 2019 Mar-Apr;21(2):107-108. doi: 10.4103/aja.aja_88_18.
9
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial-There is No Significant Reduction in Death (Yet).恩杂鲁胺对比比卡鲁胺治疗去势抵抗性前列腺癌：STRIVE试验——（目前）死亡风险无显著降低
J Clin Oncol. 2017 Jan;35(1):123. doi: 10.1200/JCO.2016.67.4630. Epub 2016 Oct 31.
10
Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer.恩杂鲁胺：向转移性去势抵抗性前列腺癌男性患者基于药代动力学的给药迈出的一步。
Clin Pharmacokinet. 2015 Oct;54(10):989-91. doi: 10.1007/s40262-015-0293-z.